Homocysteine: Update on a new risk factor

Cleveland Clinic Journal of Medicine

Volumn 64, Issue 10, 1997, Pages 543-549

  Ballal, Raj S ^a   Jacobsen, Donald W ^a,b   Robinson, Killian ^a,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND STATE UNIVERSITY   (United States)

^c F15 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

ARTERIOSCLEROSIS; BIOSYNTHESIS; BLOOD; HUMAN; PROGNOSIS; REVIEW; RISK FACTOR; THROMBOPHLEBITIS;

ARTERIOSCLEROSIS; FOLIC ACID; HOMOCYSTEINE; HUMANS; PROGNOSIS; PYRIDOXINE; RISK FACTORS; THROMBOPHLEBITIS; VITAMIN B 12;

EID: 0031267414     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.64.10.543     Document Type: Review

References (34)

1. Kang SS, Wong PW, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48(3):536-545.
2. Adams M, Smith PD, Martin D, Thompson JR, Lodwick D, Samani NJ. Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction. QJ Med 1996; 89:437-444.
3. Kluijtmans LA, van den Heuvel LP, Boers GH, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58:35-41.
4. 677T mutation. Arterioscler Thromb Vasc Biol 1996; 16:878-882.
5. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996; 93:7-9.
6. Ueland PM, Refsum H, Brattström L. Plasma homocysteine and cardiovascular disease. In: Francis RB Jr, editor. Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. New York: Marcel Dekker Inc, 1992:183-236.
7. Boushey C, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274:1049-1057.
8. Mayer EM, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27:517-527.
9. Robinson K, Mayer EL, Miller DP, et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92:2825-2830.
10. Pancharuniti N, Lewis CA, Sauberlich HE, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 1994; 59:940-948.
11. Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal coronary heart disease. JAMA 1996; 275:1893-1896.
12. 6 concentrations: Risk factors for stroke, peripheral vascular disease and coronary artery disease. Circulation. In press.
13. Giles WH, Kittner SJ, Anda RF, Croft JB, Casper ML. Serum folate and risk for ischemic stroke. First national health and nutrition examination survey epidemiologic follow-up study. Stroke 1995; 26:1166-1170.
14. Leklem JJ. Vitamin B6. In: Shils ME, Olson JA, Shike M, editors. Modern nutrition in health, disease. 8th ed. Lea & Febiger, Philadelphia, 1994:383-394.
15. Brattström L, Stavenow L, Galvard H, et al. Pyridoxine reduces cholesterol and low-density lipoprotein and increases antithrombin III activity in 80-year-old men with low plasma pyridoxal 5-phosphate. Scand J Clin Lab Invest 1990; 50:873-877.
16. Krishnamurthi S, Kakkar W. Studies on the effect of platelet inhibitors on platelet adhesion to collagen and collagen-induced human platelet activation. Thromb Haemost 1985; 53:337-342.
17. Zahavi M, Zahavi J, Kakkar W. Effect of adenylcyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3′-5′-cyclic monophosphate accumulation. Thromb Haemost 1984; 52:205-209.
18. Bostom AG, Brosnan JT, Hall B, Nadeau MR, Selhub J. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 1995; 116:59-62.
19. Robinson K, Gupta A, Dennis V, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94:2743-2748.
20. Berger PB, Jones JD, Olson U, et al. Increase in total plasma homocysteine concentration after cardiac transplantation. Mayo Clin Proc 1995; 70:125-131.
21. 6. Submitted for publication.
22. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet 1985; 37:1-31.
23. den Heijer M, Blom HJ, Gerrits WBJ, et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995; 345:882-885.
24. Kottke Marchant K, Green R, Jacobsen DW, et al. High plasma homocysteine: a risk factor for arterial and venous thrombosis in patients with normal hypercoagulation profiles. Clin Appl Thromb Hemost. In press.
25. Jacobsen DW, Savon SR, Stewart RW, et al. Limited capacity for homocysteine catabolism in vascular cells and tissues: a pathophysiologic mechanism for arterial damage in hyperhomocysteinemia? (abstract) Circulation 1995; 92(Suppl I): 104.
26. ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem. 1997; 272:25380-25385.
27. Poddar R, Sivasubramanian N, Robinson K, Jacobsen DW. Homocysteine modulates the expression of a specific cytokine (monocyte chemoattractant protein-1) in human aortic endothelial cells. (abstract) Circulation. In press.
28. Tsai J-C, Perella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91:6369-6373.
29. Welch GN, Upchurch GR, Keaney JF, Loscalzo J. Homocyst(eine decreases cell redox potential in vascular smooth muscle cells (abstract). J Am Coll Cardiol 1996; 27 (Suppl 2a):163A.
30. Lentz SR, Sobey CG, Piegors DJ, et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996; 98:24-29.
31. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocysteinemia is associated with impaired endothelial- dependent vasodilation in humans. Circulation 1997; 95:1191-1121.
32. 6 supplements in elderly people with normal serum vitamin concentrations. Lancet 1995; 346:85-89.
33. Lobo A, Naso A, Arheart K, et al. Effect of low-dose folic acid on homocysteine levels in patients with coronary disease: a randomized, placebo-controlled study. Submitted for publication.
34. Bostom AG, Shemin D, Lapane KL, et al. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 49:147-152.